相关实验视频
Updated: Jun 3, 2026

05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
怀孕期间的抗甲状腺药物治疗:丹麦PRETHYR多中心研究的第一份报告
Nanna Maria Uldall-Torp1,2, Inge Bülow Pedersen2,3, Allan Carlé2,3
1Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
The Journal of clinical endocrinology and metabolism
|March 6, 2026
概括
在怀孕期间甲状腺功能过高需要治疗以避免并发症. 这项研究揭示了使用抗甲状腺药物 (ATD) 管理格雷夫斯病 (GD) 的当前丹麦实践,并指出常见的治疗时间和药物切换.
科学领域:
- 内分泌学 在内分泌学.
- 产科 产科 产科 产科 产科
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于格雷夫斯病 (GD) 的甲状腺功能过高需要在怀孕期间进行治疗,以减轻孕产妇和胎儿的风险.
- 用于治疗的抗甲状腺药 (ATD) 可能会产生副作用,使管理策略复杂化.
研究的目的:
- 检查丹麦孕妇当代甲状腺功能障碍治疗方案.
- 在怀孕期间接受抗甲状腺药物 (ATD) 治疗的女性的特征.
主要方法:
- 丹麦多中心PRETHYR研究收集了来自GD和ATD孕妇的数据.
- 收集的信息包括母亲的特征,怀孕前的甲状腺功能测试 (TSH,TT3,TRAb),以及通过问卷和医疗记录的治疗细节.
主要成果:
- 在121名女性中,97.5%的女性患有GD. 在怀孕前已知甲状腺疾病的102人中,58.8%在怀孕期间接受了ATD.
- 接受ATD的女性具有更高的TSH,TT3和TRAb水平,并且更频繁地由内分泌学家管理.
- 治疗ATD主要是在怀孕早期,经常从甲基马 (MMI) 转换为孕前甲 (PTU).
结论:
- 这项多中心研究提供了关于丹麦GD孕妇和ATD孕妇的第一份报告.
- 这些发现揭示了丹麦怀孕人口中甲状腺功能障碍管理的当前临床方法.
更多相关视频
相关概念视频
Synthesis and Regulation of Thyroid Hormones
8.5K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
8.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
618
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618
Therapeutic Drug Monitoring: Overview and Classification
462
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
462
Therapeutic Drug Monitoring: Affecting Factors
300
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
300
Therapeutic Drug Monitoring: Drug Analysis Methods
258
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
258
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60

